Dr. Michael E. Devitt, M.D.
Internal Medicine (Internal Medicine Physician)
- Medicare participating
At a glance
- Medical school
- Indiana University School of Medicine (2011)
- Years since graduation
- 15
- In the NPI registry since
- 2011
- Medicare patients seen, 2024
- 199
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2011Medical school: Indiana University School of Medicine
- 2011Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Internal Medicine Physician primary
VA license 0101256440
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- University of Virginia Medical Center Charlottesville, VA
- Centra Health - Lynchburg Gen Hospital Lynchburg, VA
Medical groups
- University of Virginia Physicians Group (1,717 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 199
- Services billed
- 938
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 40-54 minutes | 437 | 147 |
| Established patient office or other outpatient visit, 30-39 minutes | 123 | 80 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 99 | 33 |
| Hospital discharge day management, 30 minutes or less | 17 | 17 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 16 | 16 |
| New patient office or other outpatient visit, 45-59 minutes | 16 | 16 |
| New patient office or other outpatient visit, 60-74 minutes | 12 | 12 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Abiraterone Acetate | 143 |
| Prednisone Other prescribers in Charlottesville, VA | 89 |
| Orgovyx (relugolix) | 34 |
| Oxycodone Hcl Other prescribers in Charlottesville, VA | 16 |
| Eliquis (apixaban) Other prescribers in Charlottesville, VA | 13 |
| Erleada (apalutamide) | 12 |
| Xtandi (enzalutamide) | 12 |
| Ondansetron Hcl Other prescribers in Charlottesville, VA | 11 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 1 companies reported 1 payments worth $70.17 in total to this clinician.
| Pfizer Inc. | $70.17 |
|---|
| Food and Beverage | $70.17 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 2 companies. The companies reported $142,016 in research payments for these studies, mostly to the institutions running them.
- A Phase 3, Randomized, Open-label Study of MK-5684 Versus Alternative Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castration-resistant Prostate Cancer mCRPC That Progressed On or After Prior Tr…
Merck Sharp & Dohme LLC - An openlabel randomized controlled phase 3 study of enfortumab vedotin in combination with pembrolizumab versus chemotherapy alone in previously untreated locally advanced or metastatic urothelial cancer
Pfizer Inc. - MK-5684-003# A Phase 3 Randomized, Open-label Study of MK-5684 Versus Alternative Abiraterone Acetate or Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer mCRPC Previously Treated With …
Merck Sharp & Dohme LLC
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.